Model-informed drug discovery and development in the MENA region
Author Information
Author(s): Alasmari Mohammed S., Albusaysi Salwa, Elhefnawy Marwa, Ali Ali M., Altigani Khalid, Almoslem Mohammed, Alharbi Mohammed, Alghamdi Jahad, Alsultan Abdullah
Hypothesis
How can model-informed drug discovery and development (MID3) approaches enhance clinical trial design and regulatory decisions in the MENA region?
Conclusion
The study emphasizes the need for MENA countries to adopt MID3 approaches to improve drug development efficiency and address regional health challenges.
Supporting Evidence
- MID3 can significantly enhance the efficiency and success rates of drug development tailored to regional health priorities.
- Successful case studies of applying MID3 at different phases of drug development and clinical trials were discussed.
- The study calls for MENA countries to invest in workforce training and align regulatory frameworks to support MID3.
Takeaway
This study shows that using smart models can help make better medicines faster and safer for people in the Middle East and North Africa.
Methodology
The review discusses the applications, challenges, and future prospects of MID3 in drug development, emphasizing the integration of local data and computational techniques.
Limitations
The study does not provide specific quantitative data or case studies from the MENA region.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website